Related Experiment Video
Updated: Jun 27, 2026
Basic Three-Dimensional (3D) Intestinal Model System with an Immune Component
Published on: September 1, 2023
Integrated Epithelial Models Reveal Anti-Inflammatory and Barrier Modulatory Properties of Ozoile in Inflammatory
Daniele Bravoco1,2, Giuseppina di Paola1,3, Valeria Lucci4
1Istituto di Ricerche Genetiche 'Gaetano Salvatore', Biogem Scarl, 83031 Ariano Irpino, Italy.
Abstract:
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory condition, with therapy-resistant patients undergoing surgery and a high risk of developing colorectal cancer. Novel therapeutic approaches have shown limited efficacy in IBD treatment, highlighting the need for safer and more personalized strategies. The potential of natural compounds to modulate inflammation suggests their use as a potential adjunct therapy for IBD patients. Methods: Intestinal epithelial cells organoids (IECOs) were derived from IBD and non-IBD tissues from IBD patients, and levels of inflammation markers and epithelial barrier permeability were assayed using qRT-PCR, WB, IF and leaking assays in the presence of Ozoile, an extra virgin olive oil enriched in ozonides. The Luciferase-based IBD-like organoid platform was generated for preliminary screening of anti-inflammatory drugs. Results: In this study, we showed that IBD-ECOs recapitulate tissue architecture and pathological state. We showed that Ozoile has anti-inflammatory and epithelial barrier modulatory effects and that the Luciferase IBD-like organoid model is sensitive to anti-inflammatory compounds. Conclusions: Using IECOs, the specific anti-inflammatory and regenerative properties of Ozoile were assessed. Notably, our study highlights the potential of an IBD-like organoid platform to use in high-throughput screenings for rapid selection of anti-inflammatory drugs.
Insights
Ozoile, a natural compound, demonstrates anti-inflammatory and gut barrier protective effects in inflammatory bowel disease (IBD) models. An organoid platform shows promise for screening new IBD therapies.
Area of Science:
- Gastroenterology
- Cell Biology
- Natural Product Chemistry
Background:
- Inflammatory bowel disease (IBD) presents challenges due to therapy resistance and cancer risk.
- Current treatments for IBD are limited, necessitating novel therapeutic strategies.
- Natural compounds offer potential for adjunct therapy in IBD management.
Purpose of the Study:
- To investigate the therapeutic potential of Ozoile, a natural compound, in IBD.
- To develop and validate an organoid model for IBD drug screening.
Main Methods:
- Intestinal epithelial cell organoids (IECOs) were derived from IBD and non-IBD tissues.
- Inflammation markers and barrier permeability were assessed using qRT-PCR, Western Blot, and IF assays.
- A Luciferase-based IBD-like organoid platform was created for drug screening.
Main Results:
- IBD-IECOs successfully mimicked the pathological state of IBD tissues.
- Ozoile exhibited significant anti-inflammatory and epithelial barrier-modulating effects.
- The Luciferase IBD-like organoid model demonstrated sensitivity to anti-inflammatory compounds.
Conclusions:
- Ozoile possesses specific anti-inflammatory and regenerative properties beneficial for IBD.
- The developed IBD-like organoid platform is effective for high-throughput screening of anti-inflammatory drugs.
- This study supports the use of natural compounds and advanced organoid models in personalized IBD therapy.
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:26Inflammatory Bowel Disease I: Introduction
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...